First‐Trimester Down Syndrome Screening in Renal‐Transplanted Pregnant Women: Blood Creatinine Levels Impact False‐Positive Rate
Prenatal Diagnosis · 2026
DOI: 10.1002/pd.70124 ↗Kurz gefasst
Fachartikel in der Zeitschrift Prenatal Diagnosis, 2026. Verfasst von Clément Burgy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire de Biochimie, Institut Fédératif de Biologie, CHU de Toulouse, Toulouse, France. Hauptthemen laut MEDLINE: Kidney Transplantation, Down Syndrome, Creatinine, Pregnancy Trimester, First. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Over the past few decades, several thousand pregnancies following kidney transplantation have been monitored but few studies have reported on first‐trimester Down syndrome screening. This study aimed to assess the performance of such screening and its relationship with renal function.
Method
We retrieved data on 16 pregnancies after kidney transplantation and 30 controls matched for age, weight and gestational age. First‐trimester blood creatinine levels were systematically researched. Among other variables, multiples of the median (MoM) values for free‐βhCG, pregnancy‐associated plasma protein‐A (PAPP‐A), nuchal translucency were compared. After statistical review, we combined our cases group with that of a previous study to obtain a cohort of 27 post‐transplantation pregnancies to explore correlations between variables.
Results
Median values of fβ‐hCG MoM of cases and controls were significantly different (2.02 vs. 0.92; p < 0.001) whereas those of PAPP‐A and NT MoM were not. Screen positive rate (SPR) were respectively 44% and 17% (cut‐off 1/1000). Linear regressions were observed for fβ‐hCG MoM and creatinine, but not for PAPP‐A, in our initial case group ( r = 0.699, p = 0.025) and the merged group ( r = 0.724, p < 0.001).
Conclusion
We confirmed a specific profile for first‐trimester screening variables in first‐trimester post‐transplantation pregnancies and the impact of renal function, through creatinine levels, on SPR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratoire de Biochimie, Institut Fédératif de Biologie, CHU de Toulouse, Toulouse, France.
- Service d'Obstétrique, Pôle Femme-Mère-Couple, CHU de Toulouse, Toulouse, France.
- Service de Néphrologie et Transplantation d'organes, CHU de Toulouse, Toulouse, France.
- Univ Toulouse, INSERM, CERPOP, BIOETHICS, Université Paul-Sabatier, Toulouse, France.
ORCID-Profile: Paul Guerby, Safouane M Hamdi
Zitieren
APA
Burgy, C., Chanourdie, L., Guyard-Boileau, B., Hebral, A. L., Genoux, A., Combis, M. S., Guerby, P., Vayssiere, C., & Hamdi, S. M. (2026). First‐Trimester Down Syndrome Screening in Renal‐Transplanted Pregnant Women: Blood Creatinine Levels Impact False‐Positive Rate. Prenatal Diagnosis. https://doi.org/10.1002/pd.70124
Vancouver
Burgy C, Chanourdie L, Guyard-Boileau B, Hebral AL, Genoux A, Combis MS, et al. First‐Trimester Down Syndrome Screening in Renal‐Transplanted Pregnant Women: Blood Creatinine Levels Impact False‐Positive Rate. Prenatal Diagnosis. 2026. doi:10.1002/pd.70124
BibTeX
@article{Burgy2026,
author = {Burgy, Clément and Chanourdie, Lisa and Guyard-Boileau, Béatrice and Hebral, Anne-Laure and Genoux, Annelise and Combis, Marie-Sophie and Guerby, Paul and Vayssiere, Christophe and Hamdi, Safouane M},
title = {First‐Trimester Down Syndrome Screening in Renal‐Transplanted Pregnant Women: Blood Creatinine Levels Impact False‐Positive Rate},
journal = {Prenatal Diagnosis},
year = {2026},
doi = {10.1002/pd.70124}
}
EUVIMED